Angelika Richter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angelika Richter has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Alexander Böttner
4 shared publications- Christiane Werckenthin
Institut für Medizinische Mikrobiologie, Infektions- und Seuchenmedizin, Ludwig-Maximilians-Universität München
4 shared publications - Corinna Kehrenberg
Institute for Veterinary Food Science, Faculty of Veterinary Medicine, Justus Liebig University Giessen, Giessen, Germany
4 shared publications Dieter Klarmann
4 shared publicationsGabriele Luhofer
4 shared publicationsKarl-Heinz Waldmann
4 shared publications
Latest Publications
- 6 May 2010
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 96 (2) , 136-140
Autoradiographic and pharmacological studies on the role of dopamine D3 receptors in genetically dystonic (dtsz) hamsters
- 6 May 2010
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 96 (2) , 136-140
Autoradiographic and pharmacological studies on the role of dopamine D3 receptors in genetically dystonic (dtsz) hamsters
- 1 January 2009
- Published by Georg Thieme Verlag KG in Tierärztliche Praxis Ausgabe G: Großtiere / Nutztiere
- Vol. 37 (05) , 321-329
Verabreichung von Antibiotika in Geflügelbeständen
Aus Gründen der Praktikabilität kann auf eine orale Medikation von Antibiotika zur Behandlung bakterieller Erkrankungen in Geflügelbeständen nicht verzichtet werden. Die Verabreichung von Antibiotika über das Futter oder das Trinkwasser ist jedoch mit vielen Problemen behaftet, wie Unterdosierung und Kontamination der Stalleinrichtungen, die eine Selektion von Antibiotikaresistenzen begünstigen. Auch die eingeschränkte Verfügbarkeit zugelassener Arzneimittel für verschiedene Spezies des Wirtschaftsgeflügels erschwert die Therapie bakterieller Erkrankungen in der Geflügelpraxis. Dieser Beitrag soll einen Überblick über die Probleme im Praxisalltag und mögliche Lösungsansätze geben. The oral route of administration of antibiotics for the treatment of bacterial infections is by far the most practical within poultry industry. However, the medication via food or drinking water bears several risks, such as intake of insufficient doses and contaminations of the barn, which can increase selection of resistant bacteria. Furthermore, the limited availability of antimicrobials for various poultry species complicates the therapy of bacterial diseases in practice. This overview summarises practical problems and suggestions to solve the problems.
- 1 January 2009
- Published by Georg Thieme Verlag KG in Tierärztliche Praxis Ausgabe G: Großtiere / Nutztiere
- Vol. 37 (05) , 321-329
Verabreichung von Antibiotika in Geflügelbeständen
Aus Gründen der Praktikabilität kann auf eine orale Medikation von Antibiotika zur Behandlung bakterieller Erkrankungen in Geflügelbeständen nicht verzichtet werden. Die Verabreichung von Antibiotika über das Futter oder das Trinkwasser ist jedoch mit vielen Problemen behaftet, wie Unterdosierung und Kontamination der Stalleinrichtungen, die eine Selektion von Antibiotikaresistenzen begünstigen. Auch die eingeschränkte Verfügbarkeit zugelassener Arzneimittel für verschiedene Spezies des Wirtschaftsgeflügels erschwert die Therapie bakterieller Erkrankungen in der Geflügelpraxis. Dieser Beitrag soll einen Überblick über die Probleme im Praxisalltag und mögliche Lösungsansätze geben. The oral route of administration of antibiotics for the treatment of bacterial infections is by far the most practical within poultry industry. However, the medication via food or drinking water bears several risks, such as intake of insufficient doses and contaminations of the barn, which can increase selection of resistant bacteria. Furthermore, the limited availability of antimicrobials for various poultry species complicates the therapy of bacterial diseases in practice. This overview summarises practical problems and suggestions to solve the problems.
- 28 December 2008
- Published by Elsevier in European Journal of Pharmacology
- Vol. 601 (1-3) , 99-102
Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dtsz mutant hamster
- 28 December 2008
- Published by Elsevier in European Journal of Pharmacology
- Vol. 601 (1-3) , 99-102
Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dtsz mutant hamster
- 19 February 2008
- Vol. 121, 19-26
[Layout proposal for a microtitre plate to be used in routine antimicrobial susceptibility testing of bacteria from infections of dogs and cats].
The determination of minimum inhibitory concentrations by broth microdilution is recommended as method of choice for susceptibility testing of veterinary bacterial pathogens. Accordingly, broth microdilution is used in veterinary routine diagnostic laboratories at a progressive rate. To reduce the costs of susceptibility testing, it is reasonable to develop widely accepted uniform microtitre plate layouts that are produced in large quantities. Such microtitre plate layouts have already been developed and published for the susceptibility testing of pathogens from food-producing animals. However, a microtitre plate layout, especially designed for the testing of bacteria from dogs and cats, should be available, too. The choice of the antimicrobial agents or combinations of antimicrobial agents to be included in a suitable layout should be based on the following criteria: (1) the approval and availability of an antimicrobial agent or combination of agents, (2) known cross-resistances, and (3) availability of approved clinical breakpoints. The latter point is of particular importance for the choice of the numbers of concentrations per antimicrobial agent tested and the range of test concentrations. Taking into account these aspects, a science-based layout proposal for microtitre plates, which are suitable for routine testing of bacteria from dogs and cats, is presented and discussed.
- 19 February 2008
- Vol. 121, 19-26
[Layout proposal for a microtitre plate to be used in routine antimicrobial susceptibility testing of bacteria from infections of dogs and cats].
The determination of minimum inhibitory concentrations by broth microdilution is recommended as method of choice for susceptibility testing of veterinary bacterial pathogens. Accordingly, broth microdilution is used in veterinary routine diagnostic laboratories at a progressive rate. To reduce the costs of susceptibility testing, it is reasonable to develop widely accepted uniform microtitre plate layouts that are produced in large quantities. Such microtitre plate layouts have already been developed and published for the susceptibility testing of pathogens from food-producing animals. However, a microtitre plate layout, especially designed for the testing of bacteria from dogs and cats, should be available, too. The choice of the antimicrobial agents or combinations of antimicrobial agents to be included in a suitable layout should be based on the following criteria: (1) the approval and availability of an antimicrobial agent or combination of agents, (2) known cross-resistances, and (3) availability of approved clinical breakpoints. The latter point is of particular importance for the choice of the numbers of concentrations per antimicrobial agent tested and the range of test concentrations. Taking into account these aspects, a science-based layout proposal for microtitre plates, which are suitable for routine testing of bacteria from dogs and cats, is presented and discussed.
- 14 December 2006
- Published by Wiley in Journal of Neuroscience Research
- Vol. 85 (3) , 681-691
Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice
It has been hypothesized that exposures to neurotoxic pesticides together with aging and genetic factors increase the risk for developing Parkinson's disease (PD) which is characterized by a progressive degeneration of the nigrostriatal dopaminergic pathway. Chronic treatment with the pesticide rotenone has been reported to induce parkinsonism in rats. Although transgenic mice (but not transgenic rats) are available to investigate the importance of environmental factors in genetically predisposed animals, the effects of chronic rotenone exposure have so far not been examined in intact mice. Therefore, we investigated the effects of chronic exposure to rotenone (2.5 or 4.0–5.0 mg/kg s.c. for 30–45 days) in mice aged 2.5, 5, or 12 months. During the treatment period, the effects on vitality and motor behavior were investigated. Furthermore, the toxicity of rotenone on dopaminergic nigrostriatal neurons and peripheral tissues was examined. In comparison with control mice, rotenone‐treated mice had a decreased spontaneous motor activity, but the density of nigral dopaminergic neurons failed to show any significant changes, except for a tendency to decrease in old mice treated with 4 mg/kg. At the tested doses, rotenone caused a moderate hepatic fatty degeneration. The data indicate that rotenone is not able to cause the neuropathological characteristics of PD in mice under these testing paradigms, which were similar to those of the rotenone rat model. Further studies will have to clarify whether genetic mouse models of PD might be more sensitive to the neurotoxic effects of rotenone.
- 14 December 2006
- Published by Wiley in Journal of Neuroscience Research
- Vol. 85 (3) , 681-691
Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice
It has been hypothesized that exposures to neurotoxic pesticides together with aging and genetic factors increase the risk for developing Parkinson's disease (PD) which is characterized by a progressive degeneration of the nigrostriatal dopaminergic pathway. Chronic treatment with the pesticide rotenone has been reported to induce parkinsonism in rats. Although transgenic mice (but not transgenic rats) are available to investigate the importance of environmental factors in genetically predisposed animals, the effects of chronic rotenone exposure have so far not been examined in intact mice. Therefore, we investigated the effects of chronic exposure to rotenone (2.5 or 4.0–5.0 mg/kg s.c. for 30–45 days) in mice aged 2.5, 5, or 12 months. During the treatment period, the effects on vitality and motor behavior were investigated. Furthermore, the toxicity of rotenone on dopaminergic nigrostriatal neurons and peripheral tissues was examined. In comparison with control mice, rotenone‐treated mice had a decreased spontaneous motor activity, but the density of nigral dopaminergic neurons failed to show any significant changes, except for a tendency to decrease in old mice treated with 4 mg/kg. At the tested doses, rotenone caused a moderate hepatic fatty degeneration. The data indicate that rotenone is not able to cause the neuropathological characteristics of PD in mice under these testing paradigms, which were similar to those of the rotenone rat model. Further studies will have to clarify whether genetic mouse models of PD might be more sensitive to the neurotoxic effects of rotenone.
- 1 November 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (6) , 747-753
Antidystonic effects of Kv7 (KCNQ) channel openers in thedtszmutant, an animal model of primary paroxysmal dystonia
Background and purpose: Mutations in neuronal Kv7 (KCNQ) potassium channels can cause episodic neurological disorders. Paroxysmal dyskinesias with dystonia are a group of movement disorders which are regarded as ion channelopathies, but the role of Kv7 channels in the pathogenesis and as targets for the treatment have so far not been examined.Experimental approach: In the present study, we therefore examined the effects of the activators of neuronal Kv7.2/7.3 channels retigabine (5, 7.5, 10 mg kg−1i.p. and 10, 20 mg kg−1p.o.) and flupirtine (10, 20 mg kg−1i.p.) and of the channel blocker 10,10‐bis(4‐pyridinylmethyl)‐9(10H)‐anthracenone (XE‐991, 3 and 6 mg kg−1i.p.) in thedtszmutant hamster, a model of paroxysmal dyskinesia in which dystonic episodes occur in response to stress.Key results: Retigabine (10 mg kg−1i.p., 20 mg kg−1p.o.) and flupirtine (20 mg kg−1i.p.) significantly improved dystonia, while XE‐991 caused a significant aggravation in thedtszmutant. The antidystonic effect of retigabine (10 mg kg−1i.p.) was counteracted by XE‐991 (3 mg kg−1i.p.).Conclusions and Implications: These data indicate that dysfunctions of neuronal Kv7 channels deserve attention in dyskinesias. Since retigabine and flupirtine are well tolerated in humans, the present finding of pronounced antidystonic efficacy in thedtszmutant suggests that neuronal Kv7 channel activators are interesting candidates for the treatment of dystonia‐associated dyskinesias and probably of other types of dystonias. The established analgesic effects of Kv7 channel openers might contribute to improvement of these disorders which are often accompanied by painful muscle spasms.British Journal of Pharmacology(2006)149, 747–753. doi:10.1038/sj.bjp.0706878
- 1 November 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (6) , 747-753
Antidystonic effects of Kv7 (KCNQ) channel openers in thedtszmutant, an animal model of primary paroxysmal dystonia
Background and purpose: Mutations in neuronal Kv7 (KCNQ) potassium channels can cause episodic neurological disorders. Paroxysmal dyskinesias with dystonia are a group of movement disorders which are regarded as ion channelopathies, but the role of Kv7 channels in the pathogenesis and as targets for the treatment have so far not been examined.Experimental approach: In the present study, we therefore examined the effects of the activators of neuronal Kv7.2/7.3 channels retigabine (5, 7.5, 10 mg kg−1i.p. and 10, 20 mg kg−1p.o.) and flupirtine (10, 20 mg kg−1i.p.) and of the channel blocker 10,10‐bis(4‐pyridinylmethyl)‐9(10H)‐anthracenone (XE‐991, 3 and 6 mg kg−1i.p.) in thedtszmutant hamster, a model of paroxysmal dyskinesia in which dystonic episodes occur in response to stress.Key results: Retigabine (10 mg kg−1i.p., 20 mg kg−1p.o.) and flupirtine (20 mg kg−1i.p.) significantly improved dystonia, while XE‐991 caused a significant aggravation in thedtszmutant. The antidystonic effect of retigabine (10 mg kg−1i.p.) was counteracted by XE‐991 (3 mg kg−1i.p.).Conclusions and Implications: These data indicate that dysfunctions of neuronal Kv7 channels deserve attention in dyskinesias. Since retigabine and flupirtine are well tolerated in humans, the present finding of pronounced antidystonic efficacy in thedtszmutant suggests that neuronal Kv7 channel activators are interesting candidates for the treatment of dystonia‐associated dyskinesias and probably of other types of dystonias. The established analgesic effects of Kv7 channel openers might contribute to improvement of these disorders which are often accompanied by painful muscle spasms.British Journal of Pharmacology(2006)149, 747–753. doi:10.1038/sj.bjp.0706878
- 1 October 2004
- Published by Elsevier in European Journal of Pharmacology
- Vol. 502 (1-2) , 105-108
The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dtsz mutant hamster
- 1 October 2004
- Published by Elsevier in European Journal of Pharmacology
- Vol. 502 (1-2) , 105-108
The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dtsz mutant hamster
- 10 August 2004
- Vol. 117, 245-51
[Proposals of the working group "Antibiotic resistance" for the configuration of microtitre plates to be used in routine antimicrobial susceptibility testing of bacterial pathogens from infections of large food-producing animals and mastitis cases].
Two layouts for microtitre plates, which should serve for in-vitro susceptibility testing in routine diagnostics, have been set up by the working group "Antibiotic resistance" of the German Society for Veterinary Medicine. One of these layouts was designed for the testing of bacteria from cases of mastitis and the other for bacteria from infections in large food-producing animals. The choice of the antimicrobial agents and their concentrations to be included in these layouts were based on (1) the bacteria frequently associated with the respective diseases/animals, (2) the antimicrobial agents licensed for therapeutic use in these diseases/animals, (3) the currently available breakpoints, and (4) cross-resistances between the antimicrobial agerts so far known to occur in the respective bacteria.
- 10 August 2004
- Vol. 117, 245-51
[Proposals of the working group "Antibiotic resistance" for the configuration of microtitre plates to be used in routine antimicrobial susceptibility testing of bacterial pathogens from infections of large food-producing animals and mastitis cases].
Two layouts for microtitre plates, which should serve for in-vitro susceptibility testing in routine diagnostics, have been set up by the working group "Antibiotic resistance" of the German Society for Veterinary Medicine. One of these layouts was designed for the testing of bacteria from cases of mastitis and the other for bacteria from infections in large food-producing animals. The choice of the antimicrobial agents and their concentrations to be included in these layouts were based on (1) the bacteria frequently associated with the respective diseases/animals, (2) the antimicrobial agents licensed for therapeutic use in these diseases/animals, (3) the currently available breakpoints, and (4) cross-resistances between the antimicrobial agerts so far known to occur in the respective bacteria.
- 30 March 2004
- Vol. 117, 81-7
[Antimicrobial susceptibility testing of bacteria isolated from animals: considerations concerning the predefinition of breakpoints from the clinical pharmacological viewpoint].
In vitro susceptibility tests are performed to receive information for selecting the most suitable antibacterial agent. As result of in vitro susceptibility tests, the minimum inhibitory concentration (MIC) indicates bacteria as resistant or sensitive. To determine MIC, therapeutically relevant breakpoints have to be defined. Microbiological criteria, chemical and physical characteristics as well as pharmacokinetic and toxicological (tolerance) properties of the antimicrobial compounds have to be considered in the selection of the therapeutic agent in addition to clinical experiences. Using some concentration and time dependent antibiotics as examples, it is demonstrated that the above mentioned criteria are not sufficiently considered in currently defined breakpoints.
- 30 March 2004
- Vol. 117, 81-7
[Antimicrobial susceptibility testing of bacteria isolated from animals: considerations concerning the predefinition of breakpoints from the clinical pharmacological viewpoint].
In vitro susceptibility tests are performed to receive information for selecting the most suitable antibacterial agent. As result of in vitro susceptibility tests, the minimum inhibitory concentration (MIC) indicates bacteria as resistant or sensitive. To determine MIC, therapeutically relevant breakpoints have to be defined. Microbiological criteria, chemical and physical characteristics as well as pharmacokinetic and toxicological (tolerance) properties of the antimicrobial compounds have to be considered in the selection of the therapeutic agent in addition to clinical experiences. Using some concentration and time dependent antibiotics as examples, it is demonstrated that the above mentioned criteria are not sufficiently considered in currently defined breakpoints.
- 7 October 2003
- Vol. 116, 353-61
[Antimicrobial susceptibility testing of bacteria isolated from animals: methods for in-vitro susceptibility testing and their suitability with regard to the generation of the most useful data for therapeutic applications].
In-vitro susceptibility testing provides valuable informations for choosing the most suitable antimicrobial agent for the control of bacterial infections in animals. Different diffusion and dilution methods, as conducted according to various approved performance standards, can be used to determine the in-vitro susceptibility of bacterial pathogens. In the present article, problems are discussed which arise from the use of different methods and the difficulty to interpret such results. While most approved performance standards were designed for testing of bacteria from human sources, the NCCLS document M31-A2 exclusively focusses on susceptibility testing of bacteria isolated from animals and--in contrast to all other standards--includes veterinary specific breakpoints for a number of antimicrobial agents used in veterinary medicine. Therefore, performance of in-vitro susceptibility testing of veterinary pathogens should follow the recommendations given in the NCCLS document M31-A2. The microdilution method is recommended as the method of choice for susceptibility testing. The result of a microdilution test is given as the minimum inhibitory concentration (MIC). This value provides a quantitative result which precisely indicates the degree of susceptibility of the tested bacterial strain and in return gives the veterinarian a clear guidance whether therapeutic intervention with the antibiotic in question will be successful.
- 7 October 2003
- Vol. 116, 353-61
[Antimicrobial susceptibility testing of bacteria isolated from animals: methods for in-vitro susceptibility testing and their suitability with regard to the generation of the most useful data for therapeutic applications].
In-vitro susceptibility testing provides valuable informations for choosing the most suitable antimicrobial agent for the control of bacterial infections in animals. Different diffusion and dilution methods, as conducted according to various approved performance standards, can be used to determine the in-vitro susceptibility of bacterial pathogens. In the present article, problems are discussed which arise from the use of different methods and the difficulty to interpret such results. While most approved performance standards were designed for testing of bacteria from human sources, the NCCLS document M31-A2 exclusively focusses on susceptibility testing of bacteria isolated from animals and--in contrast to all other standards--includes veterinary specific breakpoints for a number of antimicrobial agents used in veterinary medicine. Therefore, performance of in-vitro susceptibility testing of veterinary pathogens should follow the recommendations given in the NCCLS document M31-A2. The microdilution method is recommended as the method of choice for susceptibility testing. The result of a microdilution test is given as the minimum inhibitory concentration (MIC). This value provides a quantitative result which precisely indicates the degree of susceptibility of the tested bacterial strain and in return gives the veterinarian a clear guidance whether therapeutic intervention with the antibiotic in question will be successful.